Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Exenatide · 1 trial · 2 indications
Total exenatide concentration
Maximal exenatide concentration
Time to reach maximal exenatide concentration
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Exenatide Implant | EXPERIMENTAL | One Exenatide Implant that delivers approximately 52 microgram/day of exenatide will be inserted subdermally just under the skin of the upper outer arm for the 9-week treatment period. |
| Bydureon BCise (exenatide extended release) | ACTIVE_COMPARATOR | 2 mg subcutaneous injection every week for a duration of 9 weeks |
| Semaglutide | ACTIVE_COMPARATOR | 1.0 mg subcutaneous injection every week for a duration of 9 weeks |
| Name | Type | Description |
|---|---|---|
| Exenatide Implant | COMBINATION_PRODUCT | Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion. |
| Bydureon BCise (exenatide extended release) | DRUG | glucagon-like peptide-1 (GLP-1) receptor agonist |
| Semaglutide, 1.0 mg/mL | DRUG | glucagon-like peptide-1 (GLP-1) receptor agonist |
Inclusion Criteria: * BMI 27 to 40 kg/m\^2 * Estimated glomerular filtration rate (eGFR) \>/= 90 mL/min/1.73 m\^2 * HbA1c \< 6.0% and FPG \< 6.7 mol/L Exclusion Criteria: * Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being ...
Exenatide is being developed for the treatment of overweight and obesity. It is a small molecule metabolic therapy that is currently in Phase 1 clinical development. The drug is also being studied in the context of type 2 diabetes, as part of an implant formulation.
Exenatide is being developed by Vivani Medical, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol VANI. The company is conducting clinical research on an implantable form of exenatide for metabolic conditions.
Exenatide is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 1 trial for the exenatide implant has been completed, with results pending further analysis.
Exenatide has one completed Phase 1 clinical trial, identified as NCT05670379, titled 'Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant'. This trial enrolled 24 participants and was conducted in Australia, involving healthy volunteers as well as individuals with overweight, obesity, and type 2 diabetes.
Exenatide is a distinct drug being developed by Vivani Medical, Inc. It is being formulated as an implant for the treatment of overweight and obesity, and it is also being studied in the context of type 2 diabetes. No alternative names for this drug have been mentioned in the available information.